[1] 张林, 郝洁, 王立平, 等. 乳腺超声造影、彩色多普勒超声及磁共振灌注成像在评估乳腺癌新辅助化疗疗效中的对比研究[J].华中科技大学学报:医学版, 2014, 11(4):449-452. [2] Yang J, Zhang Z, Chen C, et al. MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene[J].Oncogene, 2014, 33(23):3014-3023. [3] Feeley LP, Mulligan AM, Pinnaduwage D, et al. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information[J]. Mod Pathol, 2014, 27(4):554-561. [4] 厉亚林,李波. 雌激素受体、孕激素受体及原癌基因CerbB-2表达水平与乳腺浸润性导管癌超声乳腺影像报告和数据系统分级的关系[J].医学影像学杂志,2016,1(1):64-67. [5] Henry NL, Schott AF, Hayes DF. Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer:clinical validity but not utility[J]. J Clin Oncol, 2014, 32(29):3207-3209. [6] Ma Y, Li G, Li J, et al. The diagnostic value of superb microvascular imaging (SMI) in detecting blood flow signals of breast lesions:a preliminary study comparing SMI to color doppler flow imaging[J].Medicine (Baltimore), 2015, 94(36):e1502. [7] 徐乐,何琳,陈涛. 乳腺癌超声图像特征与ER、PR、CerbB-2的相关性研究[J]. 第三军医大学学报,2016,38(2):182-186. [8] Bian T, Lin Q, Wu Z, et al. Metaplastic carcinoma of the breast:Imaging and pathological features[J].Oncol Lett, 2016, 12(5):3975-3980. [9] Guo Q, Zhang L, Di Z, et al. Assessing risk category of breast cancer by ultrasound imaging characteristics[J].Ultrasound Med Biol, 2018, 44(4):815-824. [10] 韩思维,丁炎,吴鹏西,等. 乳腺癌超声及超声造影与预后分子病理学标志物相关性研究[J].生物医学工程与临床,2016,20(3):261-265. [11] Yuan P, Xu B, Wang C, et al. Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer[J]. Oncol Lett, 2016, 11(3):2101-2105. [12] 曹亚,杨丽春. 乳腺癌超声征象与cerbB-2、Ki67、P53表达之间的相关性研究[J]. 大理大学学报,2016,1(8):70-75. [13] 姜文彬,任甫.乳腺浸润性导管癌超声征象与生物学指标相关性的研究[J].中国临床医学影像杂志, 2017, 28(2):89-94. [14] 王雯,刘纪锋. 乳腺癌超声征象与分子生物学表达的相关性研究[J].中国中西医结合影像学杂志,2016,14(4):400-405. [15] Erdogan B, Turkmen E, Yalta TD, et al. Importance of Ki-67 in human epidermal growth factor receptor 2 positive breast cancer[J].J Buon, 2015, 20(3):730-736. [16] 刘莉萍,潘慧,魏亚,等. 乳腺癌中ErbB原癌基因家族的蛋白表达与临床病理特征的关系[J].中华全科医学,2014,12(4):589-590,644. [17] 魏峥跃,赵淑敏,刘晓安,等. Ki-67、p53、CerbB-2表达与乳腺癌彩色超声征象的关系[J].癌症进展,2016,14(11):1138-1141,1152. [18] 罗琼,刘雪玲,李鸣凤,等. 乳腺癌的彩色多普勒超声征象与VEGF、CerbB-2表达的关系及其临床意义[J].海南医学,2016,27(17):2815-2817. [19] 宋晨,孙利敏. 老年乳腺癌组织雌激素受体、孕激素受体与富集AT序列的特异性结合蛋白1及人表皮生长因子受体-2表达的相关性[J].中国老年学杂志,2017,37(10):2479-2481. [20] Yamamoto S, Chishima T, Mastubara Y, et al. Variability in measuring the Ki-67 labeling index in patients with breast cancer[J].Clin Breast Cancer, 2015, 15(1):e35-39. [21] 李美莺, 吴阳, 夏寅娟, 等. 乳腺癌超声数据分级系统与雌激素受体、孕激素受体、原癌基因的相关性[J].实用临床医药杂志, 2017, 21(1):103-105. [22] 屈海鸥, 李小雷. 雄激素受体表达与老年乳腺癌患者肿瘤大小、组织学分级、淋巴结转移、雌激素受体、孕激素受体、CerBb-2的相关性[J].中国老年学杂志, 2016, 36(23):5908-5910. [23] 熊雯,安绍宇,刘健,等. 乳腺癌超声造影表现与分子生物学指标的相关性研究[J].医学影像学杂志,2014,24(10):1753-1757. |